About Fibulin-2
Fibulin-2 (FBLN2) is a protein
from Homo sapiens identified by UniProt accession
P98095, 1184 residues long.
MolForge cross-references it against 0 known binders and
263 disease associations.
Target properties
| Protein name | Fibulin-2 |
|---|
| UniProt accession | P98095 |
|---|
| Gene | FBLN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1184 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (263)
Diseases linked to this target (Open Targets).
- appendicular lean mass · score 0.41
- hematocrit · score 0.37
- BMI-adjusted hip circumference · score 0.36
- refractive error measurement · score 0.35
- hemoglobin measurement · score 0.33
- body height · score 0.32
- BMI-adjusted waist circumference · score 0.30
- corneal topography · score 0.28
- vital capacity · score 0.26
- lung adenocarcinoma · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P98095-F1 | alphafold | PREDICTED | 67.38 | — |
Amino-acid sequence (1184 residues)
MVLLWEPAGA WLALGLALAL GPSVAAAAPR QDCTGVECPP LENCIEEALE PGACCATCVQ QGCACEGYQY YDCLQGGFVR GRVPAGQSYF VDFGSTECSC PPGGGKISCQ FMLCPELPPN CIEAVVVADS CPQCGQVGCV HAGHKYAAGH TVHLPPCRAC HCPDAGGELI CYQLPGCHGN FSDAEEGDPE RHYEDPYSYD QEVAEVEAAT ALGGEVQAGA VQAGAGGPPA ALGGGSQPLS TIQAPPWPAV LPRPTAAAAL GPPAPVQAKA RRVTEDSEEE EEEEEEREEM AVTEQLAAGG HRGLDGLPTT APAGPSLPIQ EERAEAGARA EAGARPEENL ILDAQATSRS TGPEGVTHAP SLGKAALVPT QAVPGSPRDP VKPSPHNILS TSLPDAAWIP PTREVPRKPQ VLPHSHVEED TDPNSVHSIP RSSPEGSTKD LIETCCAAGQ QWAIDNDECL EIPESGTEDN VCRTAQRHCC VSYLQEKSCM AGVLGAKEGE TCGAEDNDSC GISLYKQCCD CCGLGLRVRA EGQSCESNPN LGYPCNHVML SCCEGEEPLI VPEVRRPPEP AAAPRRVSEA EMAGREALSL GTEAELPNSL PGDDQDECLL LPGELCQHLC INTVGSYHCA CFPGFSLQDD GRTCRPEGHP PQPEAPQEPA LKSEFSQVAS NTIPLPLPQP NTCKDNGPCK QVCSTVGGSA ICSCFPGYAI MADGVSCEDI NECVTDLHTC SRGEHCVNTL GSFHCYKALT CEPGYALKDG ECEDVDECAM GTHTCQPGFL CQNTKGSFYC QARQRCMDGF LQDPEGNCVD INECTSLSEP CRPGFSCINT VGSYTCQRNP LICARGYHAS DDGTKCVDVN ECETGVHRCG EGQVCHNLPG SYRCDCKAGF QRDAFGRGCI DVNECWASPG RLCQHTCENT LGSYRCSCAS GFLLAADGKR CEDVNECEAQ RCSQECANIY GSYQCYCRQG YQLAEDGHTC TDIDECAQGA GILCTFRCLN VPGSYQCACP EQGYTMTANG RSCKDVDECA LGTHNCSEAE TCHNIQGSFR CLRFECPPNY VQVSKTKCER TTCHDFLECQ NSPARITHYQ LNFQTGLLVP AHIFRIGPAP AFTGDTIALN IIKGNEEGYF GTRRLNAYTG VVYLQRAVLE PRDFALDVEM KLWRQGSVTT FLAKMHIFFT TFAL
Explore Fibulin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets